Huakang Biomedical Holdings Company Limited (HK:8622)
:8622
Want to see HK:8622 full AI Analyst Report?
Top Page
Huakang Biomedical Holdings Company Limited
(8622)
Select Model
Select Model
Rating:48Neutral
Price Target:
HK$0.37
▼(-12.86% Downside)
Action:ReiteratedDate:12/03/25
The overall stock score is primarily influenced by the company's mixed financial performance, with a strong balance sheet but weak income statement and cash flow. Technical analysis suggests a lack of strong momentum, while valuation metrics highlight profitability challenges. The absence of earnings call data and corporate events limits further insights.
Positive Factors
Balance Sheet Strength
A very high equity ratio and minimal leverage provide durable financial flexibility. This conservative capital structure reduces refinancing risk, supports continued operations during losses, and gives management time to execute operational fixes or strategic investments over the next several months.
Negative Factors
Negative Profitability
Persistent operating losses and negative EBIT/EBITDA margins show the business is not currently generating operating profits. That undermines internal reinvestment capacity and shareholder returns, and requires sustained turnaround efforts to restore durable profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance Sheet Strength
A very high equity ratio and minimal leverage provide durable financial flexibility. This conservative capital structure reduces refinancing risk, supports continued operations during losses, and gives management time to execute operational fixes or strategic investments over the next several months.
Read all positive factors
Huakang Biomedical Holdings Company Limited (8622) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$164.95M
Dividend YieldN/A
Average Volume (3M)2.14M
Price to Earnings (P/E)―
Beta (1Y)0.33
Revenue Growth11.68%
EPS Growth-16.13%
CountryHK
Employees91
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding515,472,000
10 Day Avg. Volume1,472,000
30 Day Avg. Volume2,141,866
Financial Highlights & Ratios
PEG Ratio0.43
Price to Book (P/B)1.26
Price to Sales (P/S)2.68
P/FCF Ratio-13.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Huakang Biomedical Holdings Company Limited Business Overview & Revenue Model
Company Description
Huakang Biomedical Holdings Company Limited, an investment holding company, engages in the research, development, manufacture, marketing, and sale of in-vitro diagnostic (IVD) reagents in the People's Republic of China. It offers male and female f...
How the Company Makes Money
Huakang Biomedical generates revenue through the sale of its diagnostic products and medical devices to hospitals, clinics, and healthcare providers. The company utilizes a direct sales model as well as partnerships with distributors to reach a br...
Huakang Biomedical Holdings Company Limited Financial Statement Overview
Summary
Income Statement
42
Neutral
Balance Sheet
65
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 25.77M | 25.36M | 24.63M | 25.33M | 26.13M | 21.97M |
| Gross Profit | 17.50M | 17.07M | 16.09M | 16.91M | 16.46M | 14.72M |
| EBITDA | -3.62M | -3.41M | -2.55M | 188.00K | -852.00K | -8.10M |
| Net Income | -4.75M | -4.16M | -5.78M | -3.08M | -4.22M | -11.63M |
Balance Sheet | ||||||
| Total Assets | 66.75M | 65.22M | 65.31M | 66.40M | 67.06M | 72.70M |
| Cash, Cash Equivalents and Short-Term Investments | 36.73M | 36.49M | 32.94M | 33.30M | 36.21M | 41.94M |
| Total Debt | 6.42M | 4.08M | 5.14M | 1.88M | 1.78M | 2.64M |
| Total Liabilities | 14.69M | 11.17M | 14.30M | 9.88M | 9.36M | 10.84M |
| Stockholders Equity | 52.03M | 54.05M | 51.02M | 56.52M | 57.70M | 61.86M |
Cash Flow | ||||||
| Free Cash Flow | -3.71M | -5.05M | -1.55M | 475.00K | -4.71M | -6.00M |
| Operating Cash Flow | -1.72M | -3.06M | -48.00K | 1.29M | -2.38M | -3.92M |
| Investing Cash Flow | 482.00K | -4.42M | -1.15M | -6.11M | -2.06M | -1.94M |
| Financing Cash Flow | 1.27M | 6.30M | 1.02M | 2.32M | -1.37M | -1.11M |
Huakang Biomedical Holdings Company Limited Technical Analysis
Neutral
0.42
Price Trends
0.34
Negative
0.38
Negative
0.40
Negative
Market Momentum
>-0.01
Negative
50.69
Neutral
48.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8622, the sentiment is Neutral. The current price of 0.42 is above the 20-day moving average (MA) of 0.32, above the 50-day MA of 0.34, and above the 200-day MA of 0.40, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 50.69 is Neutral, neither overbought nor oversold. The STOCH value of 48.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:8622.
Huakang Biomedical Holdings Company Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | HK$214.60M | -0.15 | -30.35% | ― | -11.89% | -290.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$882.27M | 11.90 | -48.86% | ― | -15.98% | 93.93% | |
48 Neutral | HK$164.95M | -40.12 | -11.77% | ― | 11.68% | -16.13% | |
48 Neutral | HK$616.85M | -17.91 | 9.48% | ― | -36.32% | 78.17% | |
44 Neutral | HK$156.20M | -0.38 | -69.10% | ― | 1.92% | -468.15% | |
42 Neutral | HK$157.81M | -4.22 | -30.35% | ― | -12.03% | 6.24% |
* Healthcare Sector Average
HK:8622
Huakang Biomedical Holdings Company Limited
0.33
-0.03
-8.33%
HK:0858
Extrawell Pharmaceutical Holdings Limited
0.07
0.02
43.14%
HK:1011
China NT Pharma Group Co., Ltd.
0.65
0.21
47.73%
HK:1312
Kontafarma China Holdings Ltd
0.03
<0.01
7.69%
HK:1498
PuraPharm Corp. Ltd.
0.30
-0.19
-38.54%
HK:1652
Fusen Pharmaceutical Co., Ltd.
1.18
0.92
353.85%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.